



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT

Paris, July 8 2013 - NEOVACS (Alternext Paris : ALNEV) releases its six-monthly report on the liquidity contract signed with Invest Securities.

The liquidity account had the following holdings as of June 30, 2013:

- 28,223 shares
- €151,698.16 €

For the prior six month period (December 31, 2012), the corresponding figures were:

- 25,734 shares
- €141,303.51

About NEOVACS

NEOVACS is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. The company's proprietary technology covered by five patent families that run until at least 2023 has generated to date 2 product candidates in 3 severe diseases: TNF-Kinoid for Rheumatoid Arthritis and Crohn's Disease and IFN α -Kinoid for Lupus. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr

Contacts

NEOVACS

Nathalie Trépo

+33 0 1 53 10 93 00

ntrepo@neovacs.com

Presse – ALIZE RP

Caroline Carmagnol

Christian Berg

+33 (0)1 42 68 86 43

caroline@alizerp.com

Investors / NewCap

Pierre Laurent

Valentine Brouchet

+ 33 (0) 1 44 71 94 93

neovacs@newcap.fr

